Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 09, 2019 06:05 ET | Source: BeiGene, LTD.

BioAtla and BeiGene Form Worldwide Collaboration to Develop and Commercialize Novel Conditionally Active Biologic CTLA-4 Therapy

SAN DIEGO and BEIJING, China and CAMBRIDGE, Mass., April 09, 2019 (GLOBE NEWSWIRE) -- BioAtla ®, LLC, a global clinical-stage biotechnology company focused on the development of Conditionally Active...
April 01, 2019 16:05 ET | Source: BeiGene, LTD.

BeiGene Announces Phase 1 Long-Term Exposure Data and Results from Structural and Mechanistic Analyses on Tislelizumab at the AACR Annual Meeting

CAMBRIDGE, Mass. and BEIJING, China, April 01, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
March 06, 2019 07:00 ET | Source: BeiGene, LTD.

Ambrx and BeiGene Announce Global Research and Development Collaboration to Develop Next-Generation Biologics

Ambrx to receive an upfront payment of US$10 million to apply its proprietary Expanded Genetic Code platforms to discover novel biologic drug candidates in this collaboration with BeiGene and is...
March 04, 2019 07:00 ET | Source: BeiGene, LTD.

BeiGene to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., and BEIJING, China, March 04, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
February 27, 2019 16:15 ET | Source: BeiGene, LTD.

BeiGene Reports Fourth Quarter and Full Year 2018 Financial Results

Company to Host Annual Results Conference Call Today at 6:00 p.m. EST and Investor Event in Hong Kong on February 28th at 2:30 p.m. HKT CAMBRIDGE, Mass. and BEIJING, China, Feb. 27, 2019 (GLOBE...
February 22, 2019 07:00 ET | Source: BeiGene, LTD.

BeiGene to Present at the 8th SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass. and BEIJING, China, Feb. 22, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
February 19, 2019 16:30 ET | Source: BeiGene, LTD.

BeiGene Initiates Global Phase 2 Trial of Zanubrutinib in Patients with Relapsed or Refractory Marginal Zone Lymphoma

CAMBRIDGE, Mass. and BEIJING, China, Feb. 19, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
February 13, 2019 16:30 ET | Source: BeiGene, LTD.

BeiGene to Hold Fourth Quarter and Full Year 2018 Financial Results Conference Call on February 27, 2019 and Host Investor Event in Hong Kong

CAMBRIDGE, Mass., and BEIJING, China, Feb. 13, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
February 07, 2019 07:00 ET | Source: BeiGene, LTD.

BeiGene to Present at the Guggenheim Healthcare Talks Idea Forum – Oncology Day

CAMBRIDGE, Mass., and BEIJING, China, Feb. 07, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
January 14, 2019 16:15 ET | Source: BeiGene, LTD.

BeiGene Receives U.S. FDA Breakthrough Therapy Designation for Zanubrutinib in Mantle Cell Lymphoma

CAMBRIDGE, Mass. and BEIJING, China, Jan. 14, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...